ASP9853

inhibits dimerization of inducible nitric oxide synthase

Also Known As:

3-(4-chlorophenyl)-N-(2-oxo-2-((2-oxo-2-(4-((6-(trifluoromethyl)-4-pyrimidinyl)oxy)-1-piperidinyl)ethyl)amino)-1-(2-pyridinylmethyl)ethyl)acrylamide

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 03/01/2016 - "The preclinical efficacy of ASP9853 in combination with a taxane was studied in tumor-bearing mice. " 03/01/2016 - "In addition, a Phase I open-label study of ASP9853 plus docetaxel was conducted to assess this combination in patients with advanced solid tumors. " 03/01/2016 - "Here, we report preclinical pharmacology of ASP9853 and the impact of ASP9853 in combination with a taxane on tumor volume in vivo. " 03/01/2016 - "In the clinic, patients with solid tumors that had progressed or failed to respond to previous therapies were treated with once-daily ASP9853 in combination with docetaxel once every 3 weeks to assess safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) of the combination. " 03/01/2016 - "ASP9853 in combination with docetaxel showed greater tumor growth inhibition than docetaxel alone against non-small lung cancer xenografts. "
2.	Neutropenia 03/01/2016 - "Inhibition of iNOS by ASP9853 in combination with docetaxel was not tolerable and resulted in the possible potentiation of neutropenia. "
3.	Lung Neoplasms (Lung Cancer) 03/01/2016 - "ASP9853 in combination with docetaxel showed greater tumor growth inhibition than docetaxel alone against non-small lung cancer xenografts. "

1.	taxane
2.	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
3.	Docetaxel (Taxotere)

1.	Therapeutics